The Cancer Control (CC) Program at the Ohio State University Comprehensive Cancer Center (OSUCCC), led by Electra D. Paskett, PhD, MSPH and Mary Ellen Wewers, RN, PHD, MPH, has 52 members from 19 OSU departments within the OSU Colleges of Medicine, Public Health, Arts and Sciences, Law, Nursing, Education and Human Ecology, Dentistry, and Food, Agricultural and Environmental Sciences, as well as Nationwide Children's Hospital and Cincinnati Children's Hospital. Program members provide a wealth of behavioral, basic, clinical, policy, outcomes, and social scientific knowledge and expertise not only to the CC Program, but to the OSUCCC as a whole. The overall CC Program goal is to conduct research to reduce the incidence, mortality and morbidity of cancer, which is accomplished by employing a transdisciplinary research team approach.
The Specific Aims of the CC Program are to: 1) Identify molecular, genetic, and behavioral factors related to cancer incidence and mortality; 2) Develop and test behavioral interventions to prevent or detect cancer early; and, 3) Assess and intervene on issues of cancer survivorship. An additional developing aim of the CC Program is to address policy in relation to cancer prevention, detection, and care. Within these aims, research focuses on cross-cutting themes including underserved/minority populations within our catchment area, communication research, tobacco use and toxicity (including regulatory science), and behavioral strategies that capitalize on our members' strengths, such as epidemiology, biology and behavior. The program now has 2 NCI P50-funded Centers, both showcasing not only our multi-level focus but also the transition from observational to interventional studies. In addition, many of our interventions, e.g., Patient Navigation and Bio-Behavioral Intervention to Reduce Stress after Breast Cancer, have been incorporated into clinical care. Moreover, our research has contributed to policy changes, most notably the establishment of a smoke-free campus at OSU. During this past funding period (2009 - 2014), the Program members published a total 611 articles in peer-reviewed journals of which 32% have intra-programmatic collaboration, 20% have inter-programmatic collaborations, and 404 (66%) of the publications represent multi-institutional collaborations. Many of these publications fall within each of these categories bringing the total collaborative publications to 85%. CC Program funding stands at $6.8M of which $6.2M is peer-reviewed funding and of that, $3.9M (63%) is NCI funding. CC Program investigators have enrolled 9,205 participants to research studies over the last 5 years, 64% to externally peer-reviewed studies and 34% to institutional studies, 1.2% to cooperative trial group studies and 0.8% to industry studies. Of these, 6,964 (76%) were enrolled on interventional studies and 2,241 (24%) on non-interventional studies. Future goals focus on increasing research in: 1) policy, allowing us to take advantage of health care policy initiatives; 2) molecular and genetic epidemiology and 3) patient outcomes, fostering more inter-programmatic research with clinicians.

Public Health Relevance

OVERALL NARRATIVE The Ohio State University Comprehensive Cancer Center (OSUCCC) is a matrix cancer center that integrates and leverages all of the resources of the University to achieve its broad vision of creating a cancer free world. The OSUCCC addresses the public health needs of the catchment area (the state of Ohio) through research and outreach. Research conducted within the five OSUCCC Programs focuses on ways to reduce the higher rates of lung, breast, CRC and prostate cancer as well as the higher prevalence of risky behaviors such as lack of screening, obesity, high tobacco use, and lack of HPV vaccine. Outreach efforts through the OSUCCC address the needs of underserved populations - lower education; poor; inner city African American; rural and urban Hispanic; Appalachian; rural; Amish; and Somali - by providing targeted, culturally appropriate education activities, free cancer screenings, patient navigation, community networking, environmental scans, community gardening, and addressing policy issues (eg, tobacco-free campus).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016058-41S1
Application #
9378861
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-12
Project End
2020-11-30
Budget Start
2016-12-01
Budget End
2017-11-30
Support Year
41
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Bolyard, Chelsea; Meisen, W Hans; Banasavadi-Siddegowda, Yeshavanth et al. (2017) BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy. Clin Cancer Res 23:1809-1819
Schuh, Elizabeth M; Portela, Roberta; Gardner, Heather L et al. (2017) Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia. BMC Vet Res 13:294
Kumar, Bhavna; Yadav, Arti; Brown, Nicole V et al. (2017) Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status. Oncotarget 8:14847-14859
Miller, Cecelia R; Ruppert, Amy S; Fobare, Sydney et al. (2017) The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget 8:25942-25954
Pearlman, Rachel; Frankel, Wendy L; Swanson, Benjamin et al. (2017) Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncol 3:464-471
Farren, Matthew R; Hennessey, Rebecca C; Shakya, Reena et al. (2017) The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. Mol Cancer Ther 16:417-427
Teng, Kun-Yu; Han, Jianfeng; Zhang, Xiaoli et al. (2017) Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. Mol Cancer Ther 16:312-322
Russell, Luke; Bolyard, Chelsea; Banasavadi-Siddegowda, Yeshavanth et al. (2017) Sex as a biological variable in response to temozolomide. Neuro Oncol 19:873-874
Terrazas, Cesar; de Dios Ruiz-Rosado, Juan; Amici, Stephanie A et al. (2017) Helminth-induced Ly6Chi monocyte-derived alternatively activated macrophages suppress experimental autoimmune encephalomyelitis. Sci Rep 7:40814
Saporito, Donika; Brock, Pamela; Hampel, Heather et al. (2017) Penetrance of a rare familial mutation predisposing to papillary thyroid cancer. Fam Cancer :

Showing the most recent 10 out of 2211 publications